Many a time people confuse between genetics and heredity when it comes to cancer. Cancer is a molecular disease at the level of DNA sequence that holds the story of most processes including case of cancer.
Diets and Cancer have been severally linked. Foods may prevent and some may increase your risk of getting cancer. Studies comparing diets’ risk & your genetic risk -accumulate lifetime and lifestyle risk for cancers. Check the summaries here- across thousands of patients and their conclusions. (Renal Cell , Gastric, Melanoma, Ovarian and Colorectal Cancers).
In any case, specialists now guarantee they have discovered five “superfoods” that can help ladies through the maturing procedure.Researchers now realize that both organic and natural variables assume an imperative part by they way we create and age and even in deciding our danger of maladies like growth, cardiovascular sickness, and sort 2 diabetes. This quickly developing territory of logical study is alluded to as epigenetics.
The side picture to this post is indicative of all about the essential elements of the integrative medicine wheel to include Energy Medicine, Mind/Body Medicine, Manipulative Therapies, Herbal Medicine, Lifestyle and behaviour. Medicine and medical professional in the current generation is arguably a team of specialists and allied professionals—radiation physicists, cytologists, nurse practitioners, psychiatric social workers, dental hygienists, and many more.TA common man’s expectations of health and the nature of the health care system have been altered and is frequently guided by information, goods, and services ; regulations and laws that constrain medical practice on the one hand and rarely accelerating choice in health care on the other.
During my education and endeavours in medicine, I read Betty S quote once that Where there is life, there is cancer. Although the types of cancer and their incidence (the number of new types diagnosed each year) may vary by geography, sex, race, age, and ethnicity, cancer exists in every population and has since ancient times.
New Companies Join Cancer Research UK Consortium
|Published: Thursday, December 11, 2014
Last Updated: Thursday, December 11, 2014
|Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.|
|The decision follows completion of a pilot phase to evaluate leading technologies for their ability to discover biomarkers that can detect cancer in its earliest stages, long before symptoms appear, when treatment is most likely to be effective. The technologies were tested against serum samples selected from a biobank of more than five million serum samples, collected from women as part of the UKCTOCS trial, to which Abcodia has exclusive commercial access.
Based on these findings, the three companies involved will be Caprion which specialises in proteomics, Asuragen which uses next-generation sequencing to find circulating microRNAs, and the AIT Austrian Institute of Technology using its tumour auto-antibodies platform.
This next stage of the programme will focus on identifying biomarkers for colorectal, lung, oesophageal and pancreatic cancers, chosen because of the limited availability of screening tests for these cancers and patients’ poor survival when diagnosed at a late stage.
Dr Julie Barnes, chief executive of Abcodia, said: “We are excited to work with these world leading companies to bring their cutting edge technology to this endeavour. The application of such technologies to biomarker discovery in longitudinal samples donated before the clinical presentation of cancer is a real innovation and has the potential to make a real difference to the field of early cancer detection.”
Professor Ian Jacobs, vice president at the University of Manchester, principal investigator of UKCTOCS and one of the founders of Abcodia, said: “Cancers that are diagnosed at a later stage are much more difficult to manage, so I am delighted to see the progress that this consortium is making. The experiments aimed at identifying biomarkers that could form simple, non-invasive tests for early cancer detection represent an ideal use of the biobank developed through UKCTOCS.”
Dr Keith Blundy, chief executive of Cancer Research Technology, said: “After a successful pilot, we are delighted to be able to bring additional technological capability into this collaborative effort, to add to the clinical, scientific and commercial expertise of existing partners. The biobank derived from UKCTOCS is providing us with the opportunity, through this initiative, to potentially unlock a future in which thousands of cancer cases could be detected and treated before symptoms emerge.”